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Background: Expression and activation of the cMET receptor have been implicated in tumor progression and
resistance to chemotherapy in human pancreatic cancer. In this regard we assessed the effects of targeting cMET in
pancreatic cancer models in vitro and in vivo.
Methods: Human (L3.6pl, BxP3, HPAF-II, MiaPaCa2) and murine (Panc02) pancreatic cancer cell lines, endothelial
cells (ECs) and vascular smooth muscle cells (VSMCs) were used for the experiments. Furthermore, the human
pancreatic cancer cell line MiaPaCa2 with acquired resistance to gemcitabine was employed (MiaPaCa2(G250)).
For targeting the cMET receptor, the oral available, ATP-competitive inhibitor INC280 was used. Effects of cMET
inhibition on cancer and stromal cells were determined by growth assays, western blotting, motility assays and
ELISA. Moreover, orthotopic xenogeneic and syngeneic mouse (BALB-C nu/nu; C57BL/6) models were used to
assess in vivo efficacy of targeting cMET alone and in combination with gemcitabine.
Results: Treatment with INC280 impairs activation of signaling intermediates in pancreatic cancer cells and ECs,
particularly when cells were stimulated with hepatocyte growth factor (HGF). Moreover, motility of cancer cells and
ECs in response to HGF was reduced upon treatment with INC280. Only minor effects on VSMCs were detected.
Interestingly, MiaPaCa2(G250) showed an increase in cMET expression and cMET inhibition abrogated HGF-induced
effects on growth, motility and signaling as well as DFX-hypoxia HIF-1alpha and MDR-1 expression in vitro. In vivo,
therapy with INC280 alone led to inhibition of orthotopic tumor growth in xenogeneic and syngeneic models.
Similar to in vitro results, cMET expression was increased upon treatment with gemcitabine, and combination of
the cMET inhibitor with gemcitabine improved anti-neoplastic capacity in an orthotopic syngeneic model.
Immunohistochemical analysis revealed a significant inhibition of tumor cell proliferation (Ki67) and tumor
vascularization (CD31). Finally, combination of gemcitabine with INC280 significantly prolonged survival in the
orthotopic syngeneic tumor model even when treatment with the cMET inhibitor was initiated at an advanced
stage of disease.
Conclusions: These data provide evidence that targeting cMET in combination with gemcitabine may be effective in
human pancreatic cancer and warrants further clinical evaluation.
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Pancreatic cancer is the fourth leading cause for cancer-
related death in Europe and the U.S and therefore repre-
sents one of the most aggressive malignancies [1,2].
Since pancreatic cancer is often diagnosed in locally ad-
vanced or metastatic stages, surgery as the only curative
option is possible in only 10–20% of patients [3]. So far,
gemcitabine is considered the standard chemotherapy
for advanced pancreatic cancer [3]. Although the com-
bination of 5-fluorouracil, leucovorin, irinotecan and
oxaliplatin (FOLFIRINOX) recently showed an extension
of life by 4 months when compared to gemcitabine, this
regime has severe side effects and, therefore, is only ap-
plicable for very few patients [4]. In consequence new
therapeutic options based on the molecular biology of
pancreatic cancer are urgently needed to improve the
survival of patients.
The receptor tyrosine kinase cMET and its ligand
HGF (hepatocyte growth factor) play an important role
in embryogenesis and tissue regeneration [5-7]. Binding
of HGF to its corresponding receptor cMET leads to ac-
tivation of intracellular signalling pathways including
MAPK/ERK, PI3K/AKT and FAK (reviewed in [8]). In
cancer, this confers multiple effects such as resistance to
chemotherapy, induction of angiogenesis and promotion
of metastasis (reviewed in [9]). With regards to pancre-
atic cancer, expression of cMET has been associated
with poor survival [10] and phosphorylation of cMET
has been described in patients with early distant
metastases even after complete surgical resection [11].
Moreover, involvement of cMET activation in resist-
ance to gemcitabine therapy [12], tumour cell motility
[13] and secretion of angiogenic factors [14] has been
reported in pancreatic cancer. Therefore, targeting
cMET might be a promising approach for anti-neoplastic
therapy in this devastating tumour entity.
INC280 [(also known as INCB028060); 2-fluoro-N-
methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]
triazin-2-yl)benzamide] is an orally available, small
molecule ATP competitive inhibitor of cMET. It is select-
ive for cMET, but also impairs positive (cMET-mediated)
regulation of EGFR (epidermal-growth factor receptor) and
has shown potent anti-neoplastic activity in preclinical
studies [15]. In addition, a dose-escalating clinical phase I
study showed manageable toxicity and promising
dose-dependent decreases in cMET phosphorylation
(NCT01072266). Currently, phase I and II studies for pa-
tients with advanced solid malignancies (NCT01911507,
NCT01546428, NCT01324479), hepatocellular carcin-
oma (HCC), non-small cell lung cancer (NSCLC), renal
cell carcinoma and melanoma have been launched
(NCT01737827, NCT01610336, NCT01820364). Hence,
targeting cMET with INC280 might also be a promising
treatment option for human pancreatic cancer.In the present study, we assessed the anti-neoplastic
activity of targeting cMET with INC280 in pancreatic
cancer models and found substantial in vitro inhibition
of HGF-induced cancer cell motility and –signaling, as
well as reversal of resistance-mediating properties. To
validate our findings in vivo, we initially used an ortho-
topic xenogeneic mouse model and, subsequently, an
orthotopic syngeneic mouse model, since the latter
model harbors a functional immune system. Evaluation
of INC280 in combination with gemcitabine on tumour
growth in these experimental murine models provide
in vivo evidence that targeting cMET has potential that
could be applied to improve outcomes in patients with
pancreatic cancer.
Methods
Cell culture and reagents
Human pancreatic cancer cell lines BxPC-3, MiaPaCa2,
HPAF-II (American Type Culture Collection), L3.6pl
(kindly provided by Dr. I. J. Fidler (The University of
Texas M.D. Anderson Cancer Center)) and murine
Panc02 cells (kindly provided by Prof. V. Schmitz (Uni-
versity of Bonn, Germany)) were used. Human endothe-
lial cells (endothelial cells, ECs) and vascular smooth
muscle cells (VSMCs) were purchased from Promocell
(Heidelberg, Germany). Cells were cultured in DMEM
(Dulbecco’s Modified Eagle’s Medium; PAA Laborator-
ies, Coelbe, Germany) supplemented with 15% FCS (fetal
calf serum) maintained in 5% CO2 at 37°C as described.
Human HGF was purchased from Peprotech (Hamburg,
Germany). cMET inhibitor INC280 was kindly provided
by Novartis Oncology (Basel, Switzerland) and dissolved
in DMSO (in vitro use). For in vivo use, a stock solution
with 0.5% methylcellulose and 0.1% Tween80 (Sigma-
Aldrich, Munich, Germany) was prepared and further
dissolved with water according to the manufacturer’s
protocol. Mice received INC280 always via oral gavage
around 1 p.m.. For hypoxia-mimicking, deferroxamine-
mesylate (100 μM, DFX; Sigma-Aldrich) was used.
Gemcitabine was purchased from our local pharmacy at
the University of Regensburg. For in vivo use, mice re-
ceived gemcitabine via i.p. injection in the afternoon.
To obtain cancer cell lines with acquired resistance to
gemcitabine in vitro, MiaPaCa2 cells were treated with
increasing doses of gemcitabine, starting from 10 nM up




To evaluate cytotoxic effects of INC280, cells were seeded
in 96-well plates (1 × 103/well) and exposed to various
concentrations of INC280. Experiments were performed
in complete medium and upon serum-starvation ±HGF
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as described before [16,17].
Migration assays
Migration assays with Boyden chambers (Becton Dickinson
Bioscience, Heidelberg, Germany) were performed as re-
ported [16,18]. HGF (50 ng/ml) or 15% FCS served as
chemoattractant. After 24 hours, tumour cells were fixed
and migrated cells stained (Diff-Quick reagent; Dade
Behring, Newark, NJ). Migration assays with ECs and
VSMCs were performed for 6 hours; cells that migrated
through the filters were counted in four random fields and
average numbers were calculated.
Western blot analyses for activated signaling pathways
and HIF-1α
Experiments were performed at a cellular density of 60%
to 70%. Unless otherwise indicated, cells were incubated
with increasing doses of INC280 (100, 500, 1000 nM)
for 4 or 24 hours before stimulation with HGF (50
ng/ml) for 15 minutes. Whole-cell lysates were pre-
pared as described before [17]. Membranes were sequen-
tially probed with antibodies against phospho-AktSer473,
Akt, phospho-ERKThr202/Tyr204, ERK, phospho-cMETTyr1349,
cMET, phospho-FAKTyr925, FAK (Cell Signaling, Beverly,
MA), HIF-1α (Novus Biologicals, Littleton, CO) and β-
actin (Santa Cruz Biotechnologies, Santa Cruz, CA). For
detection of HIF-1α, MiaPaCa2(G250) cells were incu-
bated for 24 hours with INC280 (500 nM) ±DFX
(100 μM) as described [19]. Antibodies were detected by
enhanced chemiluminescence (Amersham Bioscience,
Piscataway, NJ).
PCR analysis for MDR-1 expression
Expression of MDR-1 upon cMET inhibition with
INC280 was determined by real-time PCR. Preparation
of cDNA was performed as described (20). Selected
primer pairs for PCR were as follows: MDR-1 (5-TG
GCCTTaTTTTGTTGTTGGTG and 3-ATCATTGGCG
AGCCTGGTAGTC) and 18S (5′-GTAACCCGTTGAA
CCCCATT and 3′-CCATCCAATCGGTAGTAGCG).
Primers were optimized for MgCl2 and annealing, and
PCR products were confirmed by gel electrophoresis.
RT-PCR was done using the LightCycler system and
Roche Fast-Start Light Cycler-Master Hybridization
Probes master mix (Roche Diagnostics, Mannheim,
Germany).
Enzyme-linked immunosorbent assay for VEGF-A and
PDGF-B
To determine changes in VEGF-A we used an ELISA kit
specific for human VEGF-A (BioSource Europe, Nivelles,
Belgium), as reported [20]. Pancreatic cancer cells were
plated at 40-50% density and incubated with or withoutINC280 (500nM) and stimulated with DFX for 24 hours.
Similar, PDGF-B was determined using an ELISA kit
specific for human PDGF-B (Peprotech, Hamburg,
Germany). Analyses of culture supernatants were per-
formed according to the manufacturer’s protocol.
Animal models
Experiments were approved by the Institutional Animal
Care and Use Committee of the University of Regensburg
and the regional authorities. In addition, experiments were
conducted according to “Guidelines for the Welfare of
Animals in Experimental Neoplasia” published by The
United Kingdom Coordinating Committee on Cancer
Research. Mice were housed in cages (n = 5 per unit) with
tap water and food ad libitum. In addition, animals were
assessed daily for tumour-associated symptoms and body
weight was determined every other day. Effects of cMET
inhibition with INC280 were first evaluated in an orthoto-
pic pancreatic cancer model using human L3.6pl cancer
cells. Briefly, 1 × 106 L3.6pl cells were injected into the
pancreatic tail of eight-week-old male athymic nude
mice (BALB/cnu/nu, Charles River, Germany). Mice
were randomized into 3 groups (n = 8–12/group) re-
ceiving either vehicle (controls) or INC280 (10 mg/
kg/d or 20 mg/kg/d) by oral gavage based on previ-
ously reported dosing schedules [15]; treatment
started 7 days after tumour cell inoculation. Mice were
sacrificed after 28 days, tumours were excised, weighed,
and incidence of macroscopically visible liver and lymph
node metastases was determined. Subsequently, the effects
of cMET inhibition with INC280 on growth of murine
pancreatic cancer cells (Panc02) were confirmed in an
orthotopic syngeneic model. Briefly, 2.5x105 Panc02 pan-
creatic cancer cells were injected into the pancreatic tail of
eight-week-old male C57BL/6 mice (Charles River,
Germany). Mice were randomized into 2 groups (n = 7/
group) and treatment with INC280 (10 mg/kg/d) was ini-
tiated on day 7 after tumour cell inoculation, according to
the treatment schedule for orthotopic L3.6pl cells. Since
tumours are more aggressive, the experiment was termi-
nated on day 21 when mice in the control group showed
signs of advanced disease. Tumours were excised,
weighed, and macroscopically visible lymph node metasta-
ses and ascites were determined (Panc02 does not form
liver metastases in our hands).
Since gemcitabine is the current chemotherapeutic
standard for patients with pancreatic cancer, we next
evaluated a gemcitabine dosing that delays, but does not
abrogate tumour growth in our murine cancer model
(similar to the situation in patients). For this purpose we
used a subcutaneous syngeneic tumour model (Panc02,
1×105 cells) with mice (n = 5/group) being treated with
gemcitabine 50 or 100 mg/kg twice/week. Tumours
from the higher dosing group were harvested at the end
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Western blotting. Based on the results from this model
we next assessed the combination of INC280 (10 mg/kg/
d) with gemcitabine (100 mg/kg twice/week) in the
orthotopic syngeneic mouse model. To obtain a longer
treatment period, we reduced the number of cells that
were injected into the pancreatic tail to 1×105. Mice
were randomized into 4 groups (n = 7-9 mice/group)
and therapy was initiated on day 7 after tumour cell im-
plantation. On day 27 mice in the control group showed
severe signs of tumour disease and, therefore, the experi-
ment was terminated. Tumours were excised, weighed
and occurrence of metastases was determined. In
addition, tissue was harvested for immunohistochemical
analyses.
To determine the efficacy of targeting cMET with
INC280 on survival in advanced tumour stages, we first
applied a subcutaneous tumour model. 1×105 Panc02
cells were injected into the right flank of C57BL/6 mice
and randomized to 4 groups (n = 10/group). To imitate
the clinical setting in pancreatic cancer, the initial treat-
ment in 20 mice was performed with gemcitabine
(100 mg/kg twice/week) when tumours reached a size of
80 mm3. Upon progression to approximately 300 mm3,
INC280 (10 mg/kg/d) was added to 10 mice pretreated
with gemcitabine and 10 mice without any treatment.
Mice were terminated when tumours reached a size of
around 800 mm3. Since the local microenvironment has
substantial impact on tumour growth and resistance, we
finally performed a similar syngeneic orthotopic model.
Again, 1×105 Panc02 cells were injected into the pancre-
atic tail and mice were randomized to 4 groups (n = 10/
group). Gemcitabine was given from day 10 (100 mg/kg
twice/week) and INC280 (10 mg/kg/d) was added to the
regime from day 20 after tumour cell injection, based on
the results from the subcutaneous model. Mice were ter-
minated as soon as they showed signs of tumour disease.
Immunohistochemical analysis of vascularization, tumour
cell proliferation and apoptosis
To determine CD31-positive vessel area, cryosections
were obtained. Frozen tissue was fixed in cold acetone
and chloroform, washed with PBS and exposed to anti-
bodies against CD31 (1:50; Pharmingen, Germany), and
respective secondary antibody (AlexaFluor 488; 1:200).
Images were obtained in four different quadrants of
each tumour section (2 mm inside the tumour- nor-
mal tissue interface) at 20× magnification [16]. Vessel
area was determined as pixels/hpf using ImageJ version
1.46r (NIH, USA).
Ki67 staining was performed on paraffin sections.
Briefly, slides were deparaffinized in xylene, followed
by treatment with a graded series of alcohol washes
[100, 95, 70% ethanol/ddH2O (v/v)], rehydration incitrate buffer (pH6; Merck, Darmstadt, Germany), and
blocking against endogenous peroxidase with H2O2.
Slides were incubated with Ki67 primary antibody
(1:100; abcam, Cambridge, UK) at 4°C overnight. After
washing with TBS, secondary antibody (Santa Cruz
Biotechnologies, Santa Cruz, CA) was added to tissue
sections followed by incubation with diaminobenzidine
(Biozol, Eching, Germany). Negative controls were per-
formed by omitting the primary antibody. Ki67 positive
cells were counted in four fields per tumour section at
20× magnification and the average was calculated.
A terminal deoxynucleotidyl transferase-mediated nick-
end labeling detection kit (TUNEL; Promega Corp.,
Mannheim, Germany) was used to detect cell apoptosis
[20]. Four fields at 20× magnification were selected at the
proliferation front in each tumour, and TUNEL positive
cells were counted; an average value from these results
was calculated.
Statistical analysis
Statistical analyses were done using SigmaStat (Version
3.0). Results of in vivo experiments were analyzed for
significant outliers using the Grubb’s test (www.graph-
pad.com). Tumour-associated variables of in vivo experi-
ments were tested for statistical significance using the
Mann–Whitney U test for nonparametric data or
ANOVA followed by Tukey’s multiple comparison test
for more than two groups. The two-sided Student’s t-test
was applied for analysis of in vitro data. All results are
expressed as the mean ± standard error of the mean
(SEM).
Results
Effect of cMET inhibition on pancreatic cancer cells
in vitro
First, the expression of cMET as the INC280 target was
assessed in human pancreatic cancer cell lines. Results
showed that cMET is expressed in HPAF-II, BxPC3 and
L3.6pl cells, whereas MiaPaCa2 did not show detectable
expression (Figure 1A). Next, the effects of targeting
cMET with INC280 on growth of pancreatic cancer cell
lines were determined in vitro. Using MTT assays a
slight, but significant, dose-dependent growth inhibition
of HPAF-II was found only when cells were stimulated
with HGF (Figure 1B). Subsequently, migration assays
showed that cMET blockade significantly impairs HGF-
induced motility but had no effect on constitutive migra-
tion in HPAF-II cells (Figure 1C). Last, we determined
the impact of INC280 on activation of oncogenic signal-
ing pathways. Incubation of HPAF-II cells with INC280
for 4 hours or 24 hours did not affect constitutive Akt,
ERK or FAK phosphorylation. While no constitutive
cMET phosphorylation was observed upon these condi-
tions, stimulation with HGF for 15 minutes led to
Figure 1 Effects of targeting cMET on pancreatic cancer cells. A) cMET expression was detectable in HPAF-II, L3.6pl, BxPC3 but not in parental
MiaPaCa2 pancreatic cancer cell lines. B) Incubation of HPAF-II cells with the cMET inhibitor INC280 has no effect on constitutive growth. When
cells were stimulated with HGF, a significant growth increase was observed (#P < 0.05). This was abrogated by cMET inhibition with INC280
(*P < 0.05). C) HGF induces cancer cell motility (#P < 0.05) that can be efficiently blocked by INC280 (*P < 0.05). Constitutive motility remains
unaffected. D) Treatment with INC280 disrupts HGF-mediated phosphorylation of Akt, ERK and FAK after 4 and 24 hours of treatment. Results in
1B-1D are shown for HPAF-II; similar results were obtained from L3.6pl and Panc02. Bars = SEM.
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ment with INC280 completely abrogated this effect
(Figure 1D). The described observations were subse-
quently confirmed in the L3.6pl human pancreatic
cancer cell line (Additional file 1: Figure S1A-C); FAK
phosphorylation was not detectable in L3.6pl and
therefore not shown. In addition, we used the murine
pancreatic cancer cell line Panc02 to confirm these re-
sults (data not shown). Taken together, our results
show that treatment with INC280 efficiently abrogates
HGF-induced motility and oncogenic signaling in pan-
creatic cancer cell lines in vitro.
Impact of targeting cMET on gemcitabine-resistant cancer
cells in vitro
The pancreatic cancer cell line MiaPaCa2 confers a cer-
tain resistance against gemcitabine which is the accepted
standard for systemic treatment in pancreatic cancer
[21,22]. To further enforce this resistance, MiaPaCa2
cells were treated with increasing doses of gemcitabine
starting from 10 nM up to 250 nM. Interestingly,although no cMET expression was detectable in the na-
tive cell line, MiaPaCa2 cells treated with gemcitabine
showed strong expression of cMET and a slight increase
in EGFR expression (Figure 2A). Subsequently, we
compared the properties of native (parental) MiaPaCa2
cells (also named MiaPaCa2(par)) with those pre-
treated with gemcitabine (named MiaPaCa2(G250))
with regards to cMET inhibition with INC280. In
MTT assays, MiaPaCa2(par) did not respond to HGF
stimulation and thus to cMET inhibition with INC280,
as one would expect because of the missing cMET re-
ceptor (Figure 2B). In contrast, HGF strongly induced
growth of MiaPaCa2(G250) and INC280 significantly
impaired this (Figure 2C). Migration assays showed
that HGF tended to increase cancer cell motility in
MiaPaCa2(par), but INC280 did not affect either
constitutive or HGF-induced motility (Figure 2D). In
MiaPaCa2(G250) HGF led to a more than 6-fold in-
crease in motility which was abrogated by cMET
blockade (Figure 2E). Finally, Western blotting from
MiaPaCa2(par) showed only modest phosphorylation
Figure 2 Targeting cMET in parental MiaPaCa2 (MiaPaCa2(par)) and resistant MiaPaCa2 (MiaPaCa2(G250)) pancreatic cancer cell lines.
A) In MiaPaCa2(G250) cells, cMET expression was detectable whereas no cMET was found in MiaPaCa2(par). B) MiaPaCa2(par) showed little
response to cMET inhibition with INC280 even when cells were stimulated with HGF (50 ng/ml). C) Growth of MiaPaCa2(G250) was significantly
improved when cells were incubated with HGF (#P < 0.05). cMET inhibition with INC280 inhibited this growth induction (*P < 0.05). D) Migration
of MiaPaCa2(par) was increased when cells were stimulated with HGF (not significant); cMET inhibition did not affect constitutive or HGF-induced
motility in these cells. E) In MiaPaCa2(G250) stimulation with HGF led to a significant increase in cancer cell motility (#P < 0.05), which was abrogated
by targeting cMET with INC280 (*P < 0.05). F) In MiaPaCa2(par) stimulation with HGF led to weak induction of Akt and ERK phosphorylation. This was
diminished by treatment with INC280. No effects on constitutive signaling were observed. G) HGF showed strong induction of Akt, ERK and FAK
phosphorylation in MiaPaCa2(G250). Targeting cMET impairs effects on HGF-induced activation of signaling intermediates. H) Mimicking hypoxic
conditions with DFX (100 μM) significantly induced MDR-1 mRNA expression in MiaPaCa2(G250) (#P < 0.05) and cMET inhibition with INC280 abrogated
this (*P < 0.05). MDR-1 mRNA was not detectable in MiaPaCa2(par). Bars = SEM I) INC280 impairs DFX induced HIF-1α expression in
MiaPaCa2(G250) cells.
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only minor effects on Akt but impaired ERK phosphoryl-
ation (Figure 2F). In MiaPaCa2(G250), a strong phosphor-
ylation of Akt, ERK and FAK upon stimulation with HGF
was detected, which was strongly inhibited by INC280
(Figure 2G). Next, we assessed the expression of
MDR-1 as a known mediator of multidrug-resistance
[23,24]. Interestingly, MiaPaCa2(par) do not express
MDR-1 mRNA, whereas MiaPaCa2(G250) showed
MDR-1 mRNA expression which was strongly induced
upon incubation with hypoxia-mimicking DFX. Treatment
with INC280 significantly reduced MDR-1 mRNA expres-
sion in MiaPaCa2(G250) cells (Figure 2H). Searching forthe mechanism of MDR-1 regulation, we found that ex-
pression of hypoxia-induced HIF-1α, a major regulator of
MDR-1 and stromal factors such as VEGF-A, is impaired
by cMET inhibition in MiaPaCa2(G250) (Figure 3I). In
conclusion, these results indicate that cMET expres-
sion is involved in resistance to gemcitabine and
INC280 effectively inhibits HGF-induced effects in
gemcitabine-resistant pancreatic cancer cell lines.
Modulation of stromal factors in pancreatic cancer cell
lines in vitro
Since cancer cells are a major source of factors that in-
fluence the microenvironment [25], we next determined
Figure 3 Effects on VEGF-A secretion by cMET inhibition. A) cMET inhibition had no effect on constitutive or DFX-induced VEGF-A secretion
by HPAF-II pancreatic cancer cells (#P < 0.05). B) MiaPaCa2(G250) showed a significant increase in VEGF-A production compared to MiaPaCa2(par)
(#P < 0.05). However, INC280 has no effect on constitutive VEGF-A secretion in either MiaPaCa2(par) or gemcitabine-resistant MiaPaCa2(G250).
C) Hypoxia-mimicking DFX significantly induced VEGF-A secretion from MiaPaCa2(G250) (#P < 0.05). Targeting cMET significantly impaired this
effect (*P < 0.05). Bars = SEM.
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and PDGF-B in cancer cell lines. Using ELISAs for
VEGF-A and PDGF-B, we found no effect of targeting
cMET on secretion of both in HPAF-II and L3.6pl even
when cells were stimulated with hypoxia-mimicking DFX
(Figure 3A and Additional file 2: Figure S2B for HPAF-II,
Additional file 2: Figure S2A and 2C for L3.6pl). Interest-
ingly, we detected an increase in VEGF-A and PDGF-B se-
cretion in MiaPaCa2(G250) cells compared to MiaPaCa2
(par). Nonetheless, INC280 had no effect on constitutive
secretion of both factors in MiaPaCa2(par) or in Mia-
PaCa2(G250), suggesting that other cMET-independent
mechanisms are involved in this up-regulation (Figure 3B,
Additional file 2: Figure S2D). Finally, we assessed the ef-
fect of cMET inhibition on hypoxia-induced VEGF-A se-
cretion in MiaPaCa2(G250) since INC280 led to inhibition
of HIF-1α in these cells. Results showed a strong DFX-
induced increase in VEGF-A secretion that was signifi-
cantly impaired by cMET blockade (Figure 3C). Regarding
PDGF-B, incubation with DFX also led to a significant in-
duction of protein secretion, but this was not affected by
cMET blockade (Additional file 2: Figure S2E). Together,
these results suggest that targeting cMET in pancreatic
cancer cell lines has no effect on VEGF-A and PDGF-
B secretion. However, the secretion of VEGF-A in
gemcitabine-resistant cells might be affected by cMET
inhibition via inhibition of HIF-1α.Targeting cMET in stromal components (ECs, VSMCs)
in vitro
Pancreatic cancer is characterized by a strong stromal
reaction. Therefore, we subsequently examined the ef-
fects of cMET inhibition on ECs and VSMCs. MTT
assays in ECs under serum-starved conditions and
stimulation with HGF, showed a slight but significant
increase in growth that was diminished by INC280
(Additional file 3: Figure S3B). No effect upon constitu-
tive conditions was observed (Additional file 3: Figure
S3A). EC motility was significantly increased upon incu-
bation with HGF, which was strongly reduced by
INC280 (Figure 4A). Regarding activation of signaling
pathways, treatment with INC280 strongly inhibited
HGF-induced activation of Akt and ERK whereas no ef-
fects on constitutive Akt and ERK phosphorylation were
found (Figure 4B). Taken together, these results show
that INC280 affects ECs only when these cells are stimu-
lated with HGF.
Next we analyzed the impact of INC280 on VSMCs.
MTT assays showed a dose-dependent inhibition of
VSMC growth starting from INC280 (100nM) after
72 hours of incubation (Additional file 3: Figure S3C). In
contrast to ECs, stimulation with HGF upon serum-
starved conditions had no effect on VSMC growth and,
accordingly, INC280 did not have a further growth in-
hibitory effect in MTT assays (Additional file 3: Figure
Figure 4 Effects of cMET inhibition on endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). A) HGF significantly induced
motility of EC in vitro (#P < 0.05); INC280 impaired this effect (*P < 0.05). B) cMET inhibition had no effect on constitutive activation of
signaling pathways in ECs. However, HGF strongly induces Akt and ERK phosphorylation which can efficiently be inhibited by INC280. C)
Stimulation with HGF had no effect on motility of VSMCs. However, INC280 impaired constitutive motility of these cells in vitro (*P < 0.05).
D) In VSMCs, HGF had minor effects on Akt and ERK phosphorylation in vitro. INC280 impairs the effect of HGF, but has no effect on constitutive pathway
activation. Bars = SEM.
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was not induced, but targeting cMET with INC280 led
to a significant inhibition of constitutive migration
(Figure 4C). Finally, Western blotting did not show a
substantial effect of INC280 on constitutive Akt
phosphorylation and only a minor impact on ERK
phosphorylation in VSMCs (Figure 4D). These results
indicate that HGF does not affect VSMCs and cMET
inhibition with INC280, therefore, has only minor ef-
fects on these cells.
Targeting cMET impairs tumour growth in vivo
Our results so far suggest that cMET inhibition with
INC280 might be effective against pancreatic cancerFigure 5 Targeting cMET with INC280 in vivo. A) cMET inhibition signifi
model using L3.6pl human pancreatic cancer cell line. Increasing the dose
Similar growth inhibition was observed in the orthotopic syngeneic model
tumour model, treatment with gemcitabine (50 and 100 mg/kg twice/wee
when gemcitabine therapy was continued, tumours soon reentered the ex
with gemcitabine (100 mg/kg twice/week) was markedly increased as compa
inhibition of tumour growth in the orthotopic syngeneic model (*P < 0.05 vs.
effect (#P < 0.01 vs. control and #P < 0.05 vs. gemcitabine and INC280 alone). F
(Ki67) in vivo. Combination of both substances further increased the anti-proli
INC280 alone). G) Significant reduction of tumour angiogenesis was observed
CD31 positive vessel area (*P < 0.05 vs. control). H) No effect on tumour cell acells. To further address this issue we used an orthoto-
pic xenograft model with metastatic L3.6pl pancreatic
cancer cells. To elucidate a potential dose-dependent
effect, treatment with INC280 (10 and 20 mg/kg/d)
was initiated 7 days after tumour cell inoculation. Re-
sults showed a significant reduction of final tumour
weight after 28 days in both treatment groups, com-
pared to control (Figure 5A). However, no difference
between the 10 mg/kg/d and the 20 mg/kg/d group
was noted. Therefore, 10 mg/kg/d was selected as the
effective dose in follow-up experiments. Notably, we
also found a trend towards reduced liver metastases
upon cMET blockade, although this did not reach
statistical significance (Table 1). Moreover, enlargedcantly impaired tumour growth in the orthotopic xenogeneic tumour
to 20 mg/kg/d did not improve growth-inhibitory effects (*P < 0.05). B)
with murine Panc02 cells (*P < 0.05). C) In the subcutaneous syngeneic
k) led to a transient deceleration of tumour growth, however, even
ponential growth phase. D) Expression of cMET in tumours treated
red to untreated controls. E) INC280 and gemcitabine led to significant
control). Combination of both substances substantially enhanced this
) INC280 and gemcitabine significantly reduced tumour cell proliferation
ferative capacity (#P < 0.01 vs. control and #P < 0.05 vs. gemcitabine and
upon either single agent or combination therapy, as determined by
poptosis was detected by TUNEL staining.
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control group, but only 3/10 (30%) in the 10 mg/kg/d
group and 2/8 (25%) in the 20 mg/kg/d group
(Table 1); these results only describe a trend, since
statistical significance was not reached. Nonetheless,
this is of particular importance since lymph nodes are
the primary site of metastasis in pancreatic cancer. To
confirm the growth inhibitory effects of INC280, we
subsequently used the syngeneic orthotopic model
with murine Panc02 cells (2.5×105 cells). Results again
showed that cMET inhibition (10 mg/kg/d) signifi-
cantly impairs tumour growth on day 21 (Figure 5B).
In this model we also found a trend towards reduction
of lymph node metastases similar to the orthotopic
xenogeneic model (Table 1). We were not able to
examine liver metastases in the Panc02 model since
these cells do not form liver metastases in our experi-
ence. It should be noted that none of the mice treated
with INC280 showed ascites formation (Table 1). In
summary, these results clearly demonstrate that tar-
geting cMET with INC280 impairs tumour growth
and metastases in vivo.
Combination of cMET inhibition with gemcitabine
treatment in vivo
Since gemcitabine is the standard treatment for pancre-
atic cancer patients, we next addressed the issue ofTable 1 Metastases formation in the orthotopic
pancreatic cancer xenogeneic and syngeneic model
L3.6pl orthotopic model1
Liver metastases LN metastases
Positive Negative Positive Negative
Control (n = 12) 8 (66.7%) 4 (33.3%) 8 (66.7%) 4 (33.3%)
INC280 10 mg/kg/d (n = 10) 5 (50%) 5 (50%) 3 (30%) 7 (70%)
INC280 20 mg/kg/d (n = 8) 4 (50%) 4 (50%) 2 (25%) 6 (75%)
Panc02 orthotopic model2
LN metastases Ascites
Positive Negative Positive Negative
Control (n = 7) 4 (57.1%) 3 (42.9%) 4 (57.1%) 3 (42.9%)
INC280 10 mg/kg/d (n = 7) 0 7 (100%) 0 7 (100%)
Panc02 orthotopic model2
LN metastases Ascites
Positive Negative Positive Negative
Control (n = 9) 6 (66.7%) 3 (33.3%) 3 (33.3%) 6 (66.7%)
INC280 (n = 7) 1 (14.3%) 6 (85.7%) 1 (14.3%) 6 (85.7%)
gemcitabine (n = 8) 2 (25%) 6 (75%) 2 (25%) 6 (75%)
INC280+gemcitabine (n = 8) 1 (12.5%) 7 (87.5%)* 0 (0%) 8 (100%)
1does not form ascites in our hands.
2does not form liver metastases in our hands.
*P < 0.05 vs. control.combining INC280 with gemcitabine in vivo. In accord-
ance to the situation in patients, we first defined a dos-
ing for gemcitabine that has only limited therapeutic
efficacy using a subcutaneous syngeneic tumour model
(Panc02). Results showed that 50 and 100 mg/kg gemci-
tabine administered twice/week significantly delays, but
does not abrogate, tumour growth in the Panc02 model
(Figure 5C). In addition, Western blotting from these tu-
mours revealed an up-regulation of cMET expression
upon gemcitabine treatment (Figure 5D). In further
experiments, we chose to use gemcitabine 100 mg/kg
twice/week in combination with INC280 (10 mg/kg/d).
The efficacy of this combination was first assessed in
the orthotopic syngeneic model (Panc02, 1×105 cells).
Simultaneous treatment with INC280 and gemcitabine
was initiated 7 days after tumour cell implantation and
went on for 20 days. No treatment-associated side effects
(e.g. weight loss) were observed (data not shown). After
27 days results revealed a significant reduction of
tumour weight in all treatment groups; the combination
treatment was most effective showing significant tumour
reduction versus both the control and single agent ther-
apy groups (Figure 5E). Immunohistochemical work-up
revealed a significant inhibition of tumour cell prolifera-
tion (Ki67 staining) in all treatment groups, but the com-
bination treatment was clearly most effective (Figure 5F).
Regarding tumour vascularization, CD31 staining revealed
a significant reduction in all treatment groups compared
to controls, although there was no difference between the
different treatment groups (Figure 5G). No effect on
tumour cell apoptosis was observed (Figure 5H). Metasta-
ses formation was also impaired in this model with only 1/
8 mice showing enlarged lymph nodes and no ascites with
combined INC280 and gemcitabine treatment (Table 1).
These results clearly show the potential therapeutic
benefits of combining cMET inhibition with gemcita-
bine treatment.
Inhibition of cMET prolongs survival in combination with
gemcitabine in vivo
The clinical situation shows that more than 80% of pa-
tients present with an advanced tumour stage and are
initially treated with systemic chemotherapy. We ad-
dressed this issue first in a subcutaneous tumour model
(Panc02). Gemcitabine treatment (100 mg/kg twice/
week) was started when tumours reached a size of
80–100 mm3 (Figure 6A, green line). From our initial
experiments with gemcitabine in the subcutaneous
tumour model we knew that this leads to delayed
tumour growth up to a size of approximately 300 mm3
(Figure 5C). Therefore, we defined tumours >300 mm3
as clinically progressing, and used this threshold to add
INC280 as “second line” therapy (Figure 6A, red line).
Mice were sacrificed when tumours reached a size of
Figure 6 Impact of gemcitabine and INC280 combination
therapy in advanced tumour stages. A) In the subcutaneous
syngeneic mouse model, treatment with gemcitabine was initiated
when tumours reached a size of 80–100 mm3 (green line). INC280
treatment was started when tumour size exceeded 300 mm3
(red line). Gemcitabine alone led to a delay in tumour growth;
Combination of gemcitabine with cMET inhibition significantly
improved tumour growth inhibition. B) In the orthotopic syngeneic
tumour model, survival of mice was significantly prolonged with
gemcitabine therapy alone (#P < 0.05 vs. control and vs. INC280).
A significant survival improvement was observed when gemcitabine
was combined with cMET inhibition (*P < 0.001 vs. control and
P < 0.05 vs. gemcitabine).
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growth delay in vivo as expected and delayed initiation
of INC280 treatment alone has no effect on tumour
growth. In comparison, combined INC280 and gemcita-
bine treatment was the most effective therapy against
tumour progression (Figure 6A). Since the microenvir-
onment has significant impact on tumour growth and
resistance to anti-neoplastic therapies, we confirmed these
results in the orthotopic syngeneic model (Panc02). In ac-
cordance with the subcutaneous model experiments, we
initiated gemcitabine (100 mg/kg twice/week) treatment
on day 10 and added INC280 (10 mg/kg/d) on day 20.
Results from this model showed that INC280 alone has no
effect on advanced tumour growth, and gemcitabine sig-
nificantly improves survival as expected. Consistent withthe subcutaneous model results, the addition of the cMET
inhibitor INC280 to tumours pretreated with gemcitabine
was the most efficient therapy (Figure 6B). These results
strongly support the idea of adding cMET inhibition to
gemcitabine treatment, even when the pancreatic cancer
is in advanced stages.
Discussion
Pancreatic cancer is still one of the most devastating
tumour entities in humans and surgical resection pro-
vides the only curative option. However, most patients
present in stages where surgery is not an option. There-
fore, novel therapeutic opportunities are desperately
needed to improve the prognosis. Within the current
study we assess the effects of targeting cMET by using a
novel orally available ATP-competitive inhibitor in pan-
creatic cancer models. Our results show that cMET in-
hibition impairs activation of HGF-induced oncogenic
signaling intermediates in human and murine pancreatic
cancer cell lines. Moreover, treatment with the cMET in-
hibitor reduces tumour growth in vivo and prolongs sur-
vival of mice most effectively when used in combination
with gemcitabine. Taken together, our results suggest
that targeting cMET might be a novel way to improve
outcome of patients with pancreatic cancer.
Low level expression of cMET and HGF is known in
the exocrine pancreas. However, when proceeding to
PanIN or even invasive ductal adenocarcinomas, expres-
sion of both cMET and HGF greatly increases [11,26,27].
Several studies have linked activation of cMET signaling
to phosphorylation of intracellular signaling cascades
such as PI3K/Akt, MAPK/ERK or FAK in pancreatic
cancer models, leading to tumour cell invasiveness, motil-
ity and resistance to gemcitabine therapy [12,13,28-31].
Within the current study, we confirm that treatment of
cancer cell lines with the cMET inhibitor INC280 signifi-
cantly impairs HGF-induced growth and motility of
tumour cells, at least in part via inhibition of Akt, ERK
and FAK phosphorylation. Of note, there was no effect de-
tected on growth, motility and signaling intermediates in
cancer cell lines under constitutive conditions. This is of
particular importance since the stroma is known to be a
major source of HGF and Ide et al. showed that HGF ex-
pression in the stroma of pancreatic cancer specimens is
associated with poor prognosis in these patients [32].
Hence, phosphorylation of oncogenic signaling cascades
in pancreatic cancer cells via paracrine activation of the
cMET receptor might contribute to pancreatic cancer ag-
gressiveness. Therefore, it seems logical that targeting
cMET with INC280 would negate this mechanism.
A major issue in pancreatic cancer therapy is its resist-
ance to almost every systemic therapy. Gemcitabine,
which was for many years considered to be the standard
therapy for pancreatic cancer, only has response rates
Brandes et al. BMC Cancer  (2015) 15:71 Page 12 of 14between 5.6 and 13.3% [33]. Novel therapeutic regimes
such as FOLFIRINOX show response rates only around
30% and come at a cost of high toxicity in more than
50% of patients [4]. Previous studies have connected the
resistance of pancreatic cancer cell lines to gemcitabine,
with alterations in EMT (epithelial-to-mesenchymal
transition) that include the cMET receptor [34].
Moreover, a report by Li and coworkers defined cMET
as a marker for pancreatic cancer stem cells (CSC)
with a high self-renewal capacity [35]. Recently, Hage
and colleagues demonstrated that treatment with
cabozantinib, a dual inhibitor of cMET and VEGFR-2,
increases the efficacy of gemcitabine, even when cells
were resistant to this agent [12]. In our experiments
MiaPaCa2 pancreatic cancer cells also show an in-
crease in cMET expression when resistant to gemcita-
bine (MiaPaCa2(G250)). Moreover, the cMET receptor
seems to be functionally active since incubation with
HGF induces growth, motility and phosphorylation of
intracellular signaling cascades in these cells. Interestingly,
MiaPaCa2(G250) cells that are resistant to gemcitabine
express MDR-1 mRNA which is in contrast to normal
MiaPaCa2(par); MDR-1 is up-regulated in MiaPaCa2
(G250) cells under hypoxic conditions. This is of particular
importance since expression of MDR-1 and its encoding
protein P-gp have been implicated in reduced drug
up-take, thereby mediating resistance to chemotherapy
[36,37]. Regulation of MDR-1 has been linked to HIF-1 ac-
tivation/stabilization and previous reports indicate that
cMET blockade impairs this transcription factor in cancer
cells [38,39]. Indeed, we found a reduction of HIF-1α upon
cMET inhibition in MiaPaCa2(G250) cells. In conclusion,
treatment with the cMET inhibitor INC280 impairs both
hypoxia-induced MDR-1 expression and HGF-mediated
effects on growth, motility and signaling intermediates in
gemcitabine resistant cancer cells in vitro. One might
speculate that treatment with gemcitabine leads to selec-
tion of cancer cells (potentially cancer stem cells) with
high cMET expression, thereby providing a rational for
the use of cMET inhibitors in pancreatic cancer at least
when tumours become gemcitabine resistant.
We used syngeneic orthotopic pancreatic cancer models
to further evaluate our findings. The advantage of these
models is the existence of a functional immune system in
the host, and the presence of a proper local microenviron-
ment [40]. As predicted from our in vitro data, combin-
ation of gemcitabine with the cMET inhibitor INC280 was
far superior to single agent therapy in terms of tumour in-
hibition in the orthotopic model. Interestingly, this effect
correlated to inhibition of tumour cell proliferation, with
no difference in tumour cell apoptosis detected; these re-
sults are consistent with growth inhibition caused by the
combination of gemcitabine and cMET inhibitor previ-
ously reported by Li et al. [35]. However, in contrast toour study, Li and coworkers used immunocompromised
NOD/SCID mice with primary human pancreatic adeno-
carcinoma cells. Regarding apoptosis, a study by Hage and
coworkers described a significant increase in vitro when
pancreatic cancer cell lines were treated with a cMET in-
hibitor in combination with gemcitabine [12]. However,
these results were not confirmed by in vivo experiments.
Taken together, our study substantiates the rational for the
use of cMET inhibitors in combination to gemcitabine in
patients with pancreatic cancer.
The clinical situation shows that most patients present
in an advanced stage of disease, necessitating the use of
models that address this situation. We were particularly
optimistic about the strategy to use cMET inhibitors
since we found that tumours of mice treated with gemci-
tabine strongly up-regulate the cMET receptor. To
mimic the clinical situation, we chose to apply INC280
at an advanced tumour stage in the syngeneic orthotopic
survival model. Importantly, adding the cMET inhibitor
at a progressive tumour growth stage, together with
gemcitabine therapy, produced significantly prolonged
survival in mice. These results are in line with a recently
published study by Avan and colleagues showing a
significant improvement in survival when combining
gemcitabine with the ATP-competitive cMET inhibitor
crizotinib in mice bearing primary pancreatic ductal
adenocarcinoma specimen [28]. In contrast to Avan and
coworkers who simultaneously started treatment with
the inhibitor and gemcitabine 5 days after tumour im-
plantation, we selected an even later time point to begin
INC280 treatment (20 days after tumour cell inocula-
tion), and initiated gemcitabine earlier at 10 days. Since
gemcitabine remains a “first-line” therapy, and other
treatments are typically considered after the tumour
shows resistance, we feel the experimental model we
used is closer to the clinical situation.
Conclusion
In summary, the present study shows that targeting
cMET may lead to an effective inhibition of tumour
growth in pancreatic cancer, even in advanced tumour
stages. Particularly, inhibition of gemcitabine-resistance
in tumour cells by cMET inhibitors may improve current
anti-neoplastic therapy strategies for the treatment of pan-
creatic cancer patients.
Additional files
Additional file 1: Figure S1. Effects of targeting cMET on L3.6pl
pancreatic cancer cells. A) Incubation of L3.6pl cells with the cMET
inhibitor INC280 has no effect on constitutive growth. When cells were
stimulated with HGF, a significant improvement of growth was observed
(#P<0.05). This was abrogated by cMET inhibition with INC280 (*P<0.05).
B) HGF induces cancer cell motility (#P<0.05) that can efficiently be
blocked by INC280 (*P<0.05). Constitutive motility remains unaffected. C)
Brandes et al. BMC Cancer  (2015) 15:71 Page 13 of 14Treatment with INC280 disrupts HGF-mediated phosphorylation of Akt
and ERK after 4 and 24 hours of treatment. Bars=SEM.
Additional file 2: Figure S2. Effects of targeting cMET on VEGF-A and
PDGF-B secretion from cancer cells. A) Hypoxia led to a significant increase
in VEGF-A secretion from L3.6pl cancer cells (#P<0.05). INC280 did not affect
this. B) Induction with DFX led to a significant increase in PDGF-B secretion
from HPAF-II pancreatic cancer cells (#P<0.05). Targeting cMET had no
impact on this. C) Similar, DFX led to increase in PDGF-B secretion from
L3.6pl and INC280 did not reduce this in vitro (#P<0.05). D) Gemcitabine
resistant MiaPaCa2(G250) showed a higher secretion of PDGF-B compared
to regular MiaPaCa2(par) (#P<0.05). cMET inhibition had no effect on this
in vitro. E) Incubation with DFX led to a significant increase in PDGF-B
secretion from MiaPaCa2(G250) but INC280 did not affect this increase
(#P<0.05). Bars=SE.
Additional file 3: Figure S3. Effects of targeting cMET on ECs and
VSMCs. A) No effect of targeting cMET with INC280 on ECs was detected
upon constitutive conditions. B) HGF induces growth of ECs after 48 and
72 hours of incubation (#P<0.05). Incubation with INC280 impairs this
(*P<0.05). C) In VSMCs, INC280 led to inhibition of constitutive growth
upon constitutive conditions (*P<0.05). D) Upon serum-starved conditions,
no effect on constitutive growth was detectable. Similar, stimulation of
VSMCs with HGF did not affect in vitro growth. Bars = SE.
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